Filing Flows

Filing Flows › Treace Medical Concepts (TMCI) › Guidance history

Treace Medical Concepts (TMCI) guidance history: what it guided and what it reported

Treace Medical Concepts gave guidance in 3 earnings releases on file since May 8, 2026. Its releases raised guidance twice and lowered it once.

Revenue

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$202M–$212M (May 8, 2026) → raised $204M–$212M (Aug 7, 2026) → reaffirmed $206M–$210M (Nov 6, 2026)—to be reported—

Adjusted EBITDA

Every guided period is still to be reported.

PeriodGuided (and how it moved)ReportedResultvs midpoint
FY2026$4.0M–$6.0M (May 8, 2026) → lowered $3.0M–$5.0M (Aug 7, 2026) → lowered $1.0M–$2.0M (Nov 6, 2026)—to be reported—

The latest quarter

Treace Medical Concepts, Q3 2026: revenue $48.3M (-4% year over year), operating margin -23.9%, net loss $12.6M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.

Questions

Does Treace Medical Concepts beat its guidance?

Treace Medical Concepts gave guidance in 3 earnings releases on file since May 8, 2026. Its releases raised guidance twice and lowered it once.

How often does Treace Medical Concepts raise guidance?

Its earnings releases raised guidance twice and lowered it once since May 8, 2026.

Latest guidance and outlook →

Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.